Information  X 
Enter a valid email address

Novacyt S.A. (NCYT)

  Print   

Friday 20 August, 2021

Novacyt S.A.

Notice of AGM

RNS Number : 2403J
Novacyt S.A.
20 August 2021
 

 

 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

Notice of AGM

 

Paris, France and Camberley, UK - 20 August 2021 -   Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM) will be held as a closed meeting at 2pm CEST/1pm BST on Wednesday, 29 September 2021. The AGM comprises both ordinary and extraordinary general meetings.

 

Due to precautionary measures put in place by the French Government as a result of the COVID-19 pandemic, and with the health and safety of its shareholders and employees being a priority, the AGM will be held without the physical presence of shareholders.

 

The Notice of AGM and a Form of Proxy will be posted to shareholders in the week commencing 6 September 2021 and will also be available on the Company's website at this time. Shareholders are strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the Notice.

 

Shareholders will be able to view a live webcast of the AGM, details of which will be provided in the Notice of AGM. Following the AGM, a recording of the meeting will be available on the Company's website at www.novacyt.com .

 

 

 

- End -

 

For further information, please refer to   www.novacyt.com   or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[email protected] / [email protected]  

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[email protected] / [email protected]  

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[email protected]  

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of  in vitro  and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information, please refer to the website: www.novacyt.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOADKLFFFVLXBBL

a d v e r t i s e m e n t